2022 Biopharma Omics Virtual Seminar - Day 1
This online event will focus on improving the collection and processing of multi-omics data during the drug discovery process to enable the development of more effective drugs. The technologies presented are LC-MS and software solutions.
Over the course of 2 days, for 2 hours each day, you will learn about new workflows from top scientists and industry innovators and get the latest news from SCIEX.
Preliminary agenda April 25, 2022
10:05 a.m. – 10:50 a.m. CEST Chronic haloperidol treatment leads to an imbalance of synaptic excitation and inhibition of D1-MSN neurons
- presented by Bruno Manadas (Center for Neuroscience and Cell Biology, University of Coimbra)
Haloperidol is a strong antipsychotic and has high efficacy against the positive symptoms of Schizophrenia, however no efficacy against negative or cognitive symptoms has been proven. Although dopamine D2 receptor blockade can be achieved within hours after haloperidol administration, the onset of action is delayed by weeks. Using proteomic analysis and whole-cell patch-clamp recordings of the striatum of mice chronically exposed to HA, we demonstrate a possible mechanism by which haloperidol may be contributing to its beneficial long-term therapeutic effect.
10:50 a.m. – 11:20 a.m. CEST Introducing the ZenoTOF 7600 system; revealing new perspectives for biomarkers research
- presented by Heather Chassaing, SCIEX
In this presentation, we will introduce the ZenoTOF 7600 System. It combines two new innovations, the first is the Zeno trap which enhances the quality and intensity of MS/MS spectra allowing the detection and characterization of low level metabolites. The second is the choice of an alternative fragmentation technology Electron Activated Dissociation (EAD), to achieve greater depths in structural elucidation and isomer differentiation. We will discuss how by combining these two new technologies we can answer the challenging questions encountered in metabolomic workflows.
11:20 a.m. – 12:05 p.m. CEST Recent developments and applications of mass spectrometry based metabolomics
- presented by Martin Giera (Leiden University Medical Center)
In this lecture, we will discuss new concepts and recent developments in the field of mass spectrometry-based metabolomics. We will discuss “activity metabolomics” and its application in drug development as well as “enhanced in-source fragmentation/annotation (EISA)” as a simplified quantitative analysis tool.
Invited speakers
Bruno Manadas, PhD (Center for Neuroscience and Cell Biology, University of Coimbra)
Bruno Manadas is a PI at CNC and established his lab as a node of the National Mass Spectrometry Network performing mainly untargeted quantitative proteomics screenings to identify disease biomarkers and elucidate biological mechanisms. He has over 100 publications with recent advances in translational approaches applied to neurodegenerative and psychiatry disorders.
Martin Giera, PhD (Leiden University Medical Center)
Martin Giera studied pharmacy in Heidelberg and Munich. He was a visiting scientist at Harvard Medical School and the Scripps Research Institute, and is currently head of the metabolomics group at the Leiden University Medical Center. Martin is involved in several multi-national consortia, is a member of several editorial boards and is chairman of the interdisciplinary committee at FWO. He has a keen interest in metabolomics technology, drug development and biochemistry, and has published more than 150 scientific publications and books.
Nikolaus Berndt, PhD (Institute of Biochemistry, Charité - Universitätsmedizin Berlin)
Nikolaus Berndt is CSO at Doppelganger and leads a systems medicine research group at Charité - Universitätsmedizin Berlin. His research team performs metabolic and biophysical analysis, and simulations in systems medicine.
Jan Detmers, PhD (Doppelganger Biosystem GmbH, Berlin)
Jan Detmers is a multi-omics scientist and VP of Precision Medicine at Doppelganger. His team supports pharmaceutical and biotech companies in translational science and clinical study bioanalysis using proteomics-based fluxomics.
Thomas Hankemeier, PhD (Leiden University)
Thomas Hankemeier has been full professor of Analytical BioSciences at the LACDR at Leiden University since 2004, where he is principal investigator for the Analytical BioSciences and Metabolomics group. His research is aimed at innovative analytical tools for metabolomics-driven systems biology in personalized health strategies.
